Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors

NCT07402109 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT07402109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07402109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors
Lead sponsor
Erasmus Medical Center
Phase
Not applicable
Overall status
Recruiting
Start date
April 1, 2026
Completion date
January 1, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma (rcc)